Top Suppliers:I want be here
Related CAS#:
152467-53-3 1482550-35-5
100768-08-9 1489778-22-4
112448-63-2 1480765-64-7
2679816-55-6 1462419-77-7
340155-47-7 1497792-33-2

26097-80-3

26097-80-3 structure
26097-80-3 structure
  • Name: Cambendazol
  • Chemical Name: propan-2-yl N-[2-(1,3-thiazol-4-yl)-3H-benzimidazol-5-yl]carbamate
  • CAS Number: 26097-80-3
  • Molecular Formula: C14H14N4O2S
  • Molecular Weight: 302.352
  • Catalog: analytical chemistry Standard Analytical standard
  • Create Date: 2018-04-11 08:00:00
  • Modify Date: 2026-07-03 00:06:57
  • Cambendazole is one of the most effective agents for the therapy of human strongyloidiasis and [1].
Name propan-2-yl N-[2-(1,3-thiazol-4-yl)-3H-benzimidazol-5-yl]carbamate
Synonyms NSC377071;NOVAZOLE;MK 905;NOVIBEN;BONLAM
equiben
Carbamic acid, N-[2-(4-thiazolyl)-1H-benzimidazol-6-yl]-, 1-methylethyl ester
Isopropyl [2-(1,3-thiazol-4-yl)-1H-benzimidazol-5-yl]carbamate
2-(4-thiazolyl)-5-benzimidazolecbamicaciisopropylester
Camvet
propan-2-yl [2-(1,3-thiazol-4-yl)-1H-benzimidazol-5-yl]carbamate
cambendazole
isopropyl2-(4-triazolyl)-5-benzimidazolecbamate
noviben
N-[2-(4-Thiazolyl)-1H-benzimidazol-5-yl]cbamic acid 1-methylethyl ester
Carbamic acid, (2-(4-thiazolyl)-1H-benzimidazol-5-yl)-, 1-methylethyl ester
mk905
Isopropyl 2-(4-thiazolyl)-5-benzimidazolecarbamate
n-(thiazolyl-4)-2,benzimidazolyl-5,cbamated’isopropyle
novazole
cbdz
2-(4-Thiazolyl)-5-isopropoxycbonylaminobenzimidazole
[2-(4-thiazolyl)-1H-benzimidazol-5-yl]carbamic acid 1-methylethyl ester
Camdan
Isopropyl (2-(thiazol-4-yl)-1H-benzo[d]imidazol-5-yl)cbamate
Gamvet
Cambenzole
inhibit,Cambendazole,Inhibitor
Novazole
Cambenzide
isopropyl 2-(thiazol-4-yl)-3H-benzo[d]imidazol-5-ylcbamate
Cambendazole 100 μg/ml Methanol
Equiben
(2-thiazol-4-yl-1(3)H-benzoimidazol-5-yl)-carbamic acid isopropyl ester
Cambendazole, 10 mM in DMSO
CBDZ
Cbamic acid, N-[2-(4-thiazolyl)-1H-benzimidazol-6-yl]-, 1-methylethyl ester
(2-(4-THIAZOLYL)-1H-BENZIMIDAZOL-5-YL)CBAMIC ACID, 1-METHYLETHYL ESTER
cambenzole
NOE [French]
(2-(4-thiazolyl)-1h-benzimidazol-5-yl)-cbamicaci1-methylethylester
Noviben
Bonlam
C10937000 Cambendazole
propan-2-yl N-[2-(1,3-thiazol-4-yl)-1H-1,3-benzodiazol-5-yl]cbamate
5-isopropoxycarbonylamino-2-(4'-thiazolyl)-benzimidazole
bonlam
Cambendazole 100 μg/mL in Acetonitrile
Description Cambendazole is one of the most effective agents for the therapy of human strongyloidiasis and [1].
Related Catalog
References

[1]. Bicalho SA, et al. Cambendazole in the treatment of human strongyloidiasis. Am J Trop Med Hyg. 1983 Sep;32(5):1181-3.

Density 1.4±0.1 g/cm3
Melting Point 212-214℃ (ethyl acetate hexane )
Molecular Formula C14H14N4O2S
Molecular Weight 302.352
Exact Mass 302.083740
PSA 108.14000
LogP 2.90
Index of Refraction 1.694

CHEMICAL IDENTIFICATION

RTECS NUMBER :
DD6538000
CHEMICAL NAME :
5-Benzimidazolecarbamic acid, 2-(4-thiazolyl)-, isopropyl ester
CAS REGISTRY NUMBER :
26097-80-3
LAST UPDATED :
199612
DATA ITEMS CITED :
12
MOLECULAR FORMULA :
C14-H14-N4-O2-S
MOLECULAR WEIGHT :
302.38
WISWESSER LINE NOTATION :
T56 BM DNJ GMVOY1&1 C- ET5N CSJ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
80480 ug/kg
SEX/DURATION :
female 8-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
60400 ug/kg
SEX/DURATION :
female 8-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
60800 ug/kg
SEX/DURATION :
female 8-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
80800 ug/kg
SEX/DURATION :
female 8-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
348 mg/kg
SEX/DURATION :
female 6-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
348 mg/kg
SEX/DURATION :
female 6-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
75 mg/kg
SEX/DURATION :
female 21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
75 mg/kg
SEX/DURATION :
female 21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

MUTATION DATA

TYPE OF TEST :
Mutation test systems - not otherwise specified
TEST SYSTEM :
Mammal - domestic Leukocyte
DOSE/DURATION :
1 mg/L
REFERENCE :
THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 31,505,1976
Symbol GHS08
GHS08
Signal Word Warning
Hazard Statements H361
Precautionary Statements P281
Hazard Codes Xn
Risk Phrases 63
Safety Phrases 36/37
RIDADR NONH for all modes of transport
RTECS DD6538000
25893-06-5 structure

25893-06-5

108-23-6 structure

108-23-6

~%

26097-80-3 structure

26097-80-3

Literature: Merck and Co., Inc. Patent: US3956488 A1, 1976 ;
5307-14-2 structure

5307-14-2

~%

26097-80-3 structure

26097-80-3

Literature: Rajappa, S.; Sreenivasan, R. Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1980 , vol. 19, # 7 p. 539 - 541
30713-39-4 structure

30713-39-4

~%

26097-80-3 structure

26097-80-3

Literature: Rajappa, S.; Sreenivasan, R. Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1980 , vol. 19, # 7 p. 539 - 541
3364-80-5 structure

3364-80-5

35198-67-5 structure

35198-67-5

~%

26097-80-3 structure

26097-80-3

Literature: Rajappa, S.; Sreenivasan, R. Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1980 , vol. 19, # 7 p. 539 - 541
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:26097-80-3 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 26097-80-3 | Chemsrc address: https://m.chemsrc.com/en/baike/596070.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2026 ChemSrc All Rights Reserved